Alpha Teknova (TKNO) investor relations material

Executive summary

• Q1 2026 revenue reached $11.1 million, up 13% year-over-year, driven by strong Clinical Solutions growth (up 85%) and steady Lab Essentials performance.

• Gross margin improved to 34.2% from 30.7% year-over-year, reflecting operational efficiencies and higher revenue.

• Net loss was $4.6 million, a slight improvement from $4.7 million in Q1 2025, with diluted EPS at $(0.08) versus $(0.09) prior year.

• Adjusted EBITDA loss narrowed to $(2.0) million from $(2.5) million year-over-year.

• Investments in sales, marketing, automation, and digitization are expected to drive future growth and efficiency.

Financial highlights

• Lab Essentials revenue was $8.4 million (+3% YoY); Clinical Solutions revenue was $2.1 million (+85% YoY).

• Gross profit was $3.8 million, up from $3.0 million YoY; operating expenses totaled $8.1 million.

• Free cash outflow improved to $3.6 million from $4.3 million YoY.

• Cash and equivalents plus short-term investments totaled $17.8 million at quarter-end; total borrowings were $13.2 million.

• Net loss per diluted share: $(0.08) in Q1 2026 vs. $(0.09) YoY.

Outlook and guidance

• 2026 revenue guidance reiterated at $42–$44 million, implying ~6% growth.

• Gross margin expected in the mid-30% range for 2026.

• Free cash outflow for 2026 expected to be less than $10 million.

• Adjusted EBITDA positive expected at $52–$57 million annualized revenue; positive quarter possible by end of 2027.

• Investments in commercial capabilities expected to drive double-digit revenue growth in 2027, targeting 20% growth.